UKALL X--an effective treatment for stage III mediastinal non-Hodgkin's lymphoma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 2334201.
- Also identified by PMC identifier 1792248.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fifteen children with mediastinal non-Hodgkin's lymphoma were treated with MRC UKALL X, the current national protocol for acute lymphoblastic leukaemia. The treatment was well tolerated, and in a minimum follow up period of 46 months the event free survival of 93% was significantly better than that in a group of historical controls treated with intermittent chemotherapy regimens whose survival was only 57%. We conclude that intensive induction and consolidation treatment, with continued oral drugs, provides an effective approach to the management of mediastinal non-Hodgkin's lymphoma.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Lymphoma, Non-Hodgkin
- Mediastinal Neoplasms